<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-162828" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Semaglutide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kommu</surname>
            <given-names>Sharath</given-names>
          </name>
          <aff>Marshfield Clinic Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Whitfield</surname>
            <given-names>Philip</given-names>
          </name>
          <aff>University of Kentucky</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sharath Kommu declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Philip Whitfield declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-162828.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is approved by the US Food and Drug Administration (FDA) as 3 separate brand name medications&#x02014;Ozempic&#x000ae;,&#x000a0;Wegovy<sup>&#x000ae;</sup>, and Rybelsus<sup>&#x000ae;</sup>.&#x000a0;Each brand name comes with its own associated indications, preparations, and dosages to consider.&#x000a0;Due to the increased complexity involved, special&#x000a0;attention is necessary for every FDA-approved indication and current off-label use.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p><bold>Rybelsus<sup>&#x000ae;</sup> tablets:</bold> This brand has received FDA approval as an adjunct to diet and exercise for enhancing glycemic control in adults with type 2 diabetes mellitus (T2DM).</p>
        <p><bold>Ozempic<sup>&#x000ae;</sup>&#x000a0;injection:</bold> This brand is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with&#x000a0;T2DM. This injection also provides an additional indication of reducing the risk of major adverse cardiovascular events, such as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, in patients with and without T2DM and established cardiovascular disease.</p>
        <p><bold>Wegovy<sup>&#x000ae;</sup>&#x000a0;injection:</bold> In a recent development, semaglutide received FDA approval as an adjunct under the brand name Wegovy<sup>&#x000ae;</sup>&#x000a0;for promoting weight loss in individuals dealing with obesity and overweight. Wegovy<sup>&#x000ae;</sup> injection is used in combination with a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity., defined by an initial body mass index (BMI) of 30 kg/m&#x000b2; or higher. This&#x000a0;injection&#x000a0;is also approved for those who are overweight, with a BMI of 27 kg/m&#x000b2; or higher, in the presence of at least a weight-related comorbid condition such as hypertension, T2DM, or dyslipidemia. The FDA&#x000a0;has also approved its use for pediatric patients aged 12 and older with an initial BMI at or above the 95th percentile for their age and sex.</p>
        <p><bold>T2DM and reduction of major cardiovascular events:&#x000a0;</bold>The SUSTAIN clinical trials have exhibited favorable outcomes in reducing&#x000a0;hemoglobin A1C (HbA1c)&#x000a0; in patients with&#x000a0;T2DM through the weekly subcutaneous semaglutide brand name Ozempic<sup>&#x000ae;</sup>. These trials compared semaglutide injection to placebo (SUSTAIN 1),&#x000a0;sitagliptin (SUSTAIN 2),&#x000a0;exenatide extended-release (SUSTAIN 3), daily insulin glargine with metformin and/or a sulfonylurea (SUSTAIN 4), and basal insulin with or without metformin (SUSTAIN 5).<xref ref-type="bibr" rid="article-162828.r1">[1]</xref><xref ref-type="bibr" rid="article-162828.r2">[2]</xref><xref ref-type="bibr" rid="article-162828.r3">[3]</xref><xref ref-type="bibr" rid="article-162828.r4">[4]</xref><xref ref-type="bibr" rid="article-162828.r5">[5]</xref>&#x000a0;Each trial demonstrated statistically significant reductions in HbA1c with semaglutide.</p>
        <p>Upon further examination of signals indicating cardiovascular benefits identified in the first&#x000a0;5 SUSTAIN trials, the SUSTAIN 6 trial examined the effects of semaglutide (Ozempic<sup>&#x000ae;</sup>) versus placebo over 2 years on a composite outcome comprising cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. <xref ref-type="bibr" rid="article-162828.r6">[6]</xref>&#x000a0;The estimated hazard ratio for the time-to-first event of the composite outcome was 0.74 (95% CI; 0.58-0.95), indicating the superiority of semaglutide&#x000a0;(Ozempic<sup>&#x000ae;</sup>) over placebo.</p>
        <p>Following the positive findings from the SUSTAIN clinical trial program, the FDA approved weekly subcutaneous semaglutide (Ozempic<sup>&#x000ae;</sup>) as an adjunct to diet and exercise for managing&#x000a0;T2DM in adults. In addition, Ozempic<sup>&#x000ae;&#x000a0;</sup>is approved for reducing the risk of major cardiovascular events, including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, in adults with T2DM and established cardiovascular disease.</p>
        <p>The PIONEER clinical trials program has demonstrated&#x000a0;the effectiveness of oral semaglutide (Rybelsus<sup>&#x000ae;</sup>) in managing&#x000a0;T2DM compared to placebo (PIONEER 1),&#x000a0;empagliflozin (PIONEER&#x000a0; 2),&#x000a0;sitagliptin with or without metformin and/or a sulfonylurea&#x000a0;(PIONEER&#x000a0;3 and PIONEER 7),&#x000a0;liraglutide&#x000a0;(PIONEER 4), and basal insulin with or without metformin&#x000a0;(PIONEER 8).<xref ref-type="bibr" rid="article-162828.r7">[7]</xref><xref ref-type="bibr" rid="article-162828.r8">[8]</xref><xref ref-type="bibr" rid="article-162828.r9">[9]</xref><xref ref-type="bibr" rid="article-162828.r10">[10]</xref><xref ref-type="bibr" rid="article-162828.r11">[11]</xref><xref ref-type="bibr" rid="article-162828.r12">[12]</xref><xref ref-type="bibr" rid="article-162828.r13">[13]</xref>&#x000a0;The PIONEER 6 trial examined the benefits of oral semaglutide (Rybelsus<sup>&#x000ae;</sup>) on the risk of major cardiovascular events similar to the aforementioned SUSTAIN 6 trial. In this trial, noninferiority with placebo was demonstrated in the composite outcome of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.<xref ref-type="bibr" rid="article-162828.r14">[14]</xref></p>
        <p>Based on the favorable results observed in the&#x000a0;T2DM trials, the FDA has approved oral semaglutide (Rybelsus<sup>&#x000ae;</sup>) as an adjunct to diet and exercise for managing T2DM. This marks the first approval of an oral GLP-1 receptor agonist for T2DM management. Unlike injectable semaglutide (Ozempic<sup>&#x000ae;</sup>), oral semaglutide (Rybelsus<sup>&#x000ae;</sup>) does not decrease major cardiovascular events.</p>
        <p><bold>Chronic weight management:&#x000a0;</bold>The Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program meticulously investigated the effects of weekly subcutaneous Semaglutide under the brand name&#x000a0;Wegovy<sup>&#x000ae;</sup> on weight loss in adult patients with obesity (BMI &#x02265;30 kg/m<sup>2</sup>)&#x000a0;or in patients who are overweight (BMI &#x02265;27 kg/m<sup>2</sup>) with comorbidities.<xref ref-type="bibr" rid="article-162828.r15">[15]</xref><xref ref-type="bibr" rid="article-162828.r16">[16]</xref><xref ref-type="bibr" rid="article-162828.r17">[17]</xref><xref ref-type="bibr" rid="article-162828.r18">[18]</xref><xref ref-type="bibr" rid="article-162828.r19">[19]</xref> Following the positive outcomes observed in the 4 STEP trials (STEPs 1, 2, 3, and 4),&#x000a0;the FDA has approved the use of 2.4 mg weekly subcutaneous semaglutide for chronic weight management in adult patients with obesity and in patients who are overweight with&#x000a0;at least 1 weight-related condition, such as hypertension, T2DM, or dyslipidemia.</p>
        <p>The recommended approach for weight management includes the integration of semaglutide&#x000a0;with a balanced diet and regular exercise.&#x000a0;Another active comparator trial, the STEP 8 trial, compared subcutaneous weekly semaglutide (Wegovy<sup>&#x000ae;</sup>) to subcutaneous daily liraglutide, revealing semaglutide's superiority in the primary outcome of mean percentage change in body weight.<xref ref-type="bibr" rid="article-162828.r20">[20]</xref></p>
        <p>The STEP TEENS trial examined the efficacy and safety of semaglutide (Wegovy<sup>&#x000ae;</sup>) compared to placebo in adolescents aged 12 to less than 18 with obesity. This trial revealed that subcutaneous semaglutide&#x000a0;(Wegovy<sup>&#x000ae;</sup>) at a dosage of 2.4 mg weekly, along with lifestyle interventions, provided superior reductions in BMI in adolescents than placebo and lifestyle interventions.<xref ref-type="bibr" rid="article-162828.r21">[21]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The FDA has approved using semaglutide for weight loss, marketed under the brand name Wegovy<sup>&#x000ae;</sup>. The recommended standard maintenance dosage for weight management is 2.4 mg, administered through weekly subcutaneous self-injections. With growing interest in semaglutide for weight control, healthcare professionals are responding to the demand by occasionally prescribing alternative brands of semaglutide, such as Ozempic<sup>&#x000ae;</sup> and Rybelsus<sup>&#x000ae;</sup>, for off-label use (using a drug approved by the FDA for a different purpose). Differences in insurance coverage between Wegovy&#x000ae; versus Ozempic&#x000ae; and Rybelsus&#x000ae; may also fuel this off-label use.&#x000a0;</p>
        <p>The FDA issued a postmarket drug safety alert regarding the&#x000a0;prevalence of compounded and counterfeit preparations of semaglutide. The increasing popularity of semaglutide for weight loss&#x000a0;is a driving force behind compounded and counterfeit preparations. The healthcare team should advise patients that they "should only obtain drugs containing semaglutide with a prescription from a licensed health care provider, and obtain medicines only from state-licensed pharmacies or outsourcing facilities registered with FDA."</p>
      </sec>
      <sec id="article-162828.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Semaglutide operates as a GLP-1 receptor agonist, sharing a remarkable 94% structural homology with human GLP.<xref ref-type="bibr" rid="article-162828.r22">[22]</xref>. The mechanisms through which semaglutide delivers its benefits in lowering blood glucose levels and promoting weight loss involve the activation of GLP-1 receptors primarily located in the gastrointestinal tract, pancreas, and brain.</p>
        <p>Upon activation of the GLP-1 receptor, semaglutide enhances glucose-dependent insulin secretion, providing a physiological response to elevated blood glucose levels after a meal.<xref ref-type="bibr" rid="article-162828.r23">[23]</xref> Simultaneously, it slows gastric emptying, increases pancreatic &#x003b2;-cell proliferation, and reduces glucagon release, contributing to an overall reduction in appetite.<xref ref-type="bibr" rid="article-162828.r23">[23]</xref><xref ref-type="bibr" rid="article-162828.r24">[24]</xref></p>
        <p>Furthermore, semaglutide's interaction with GLP-1 receptors in the hypothalamus&#x000a0;may mitigate sensations of hunger, alleviate food cravings, and enhance the feelings of satiety.<xref ref-type="bibr" rid="article-162828.r25">[25]</xref><xref ref-type="bibr" rid="article-162828.r26">[26]</xref> These multifaceted actions contribute to the comprehensive metabolic effects of semaglutide in managing blood glucose levels and facilitating weight loss.</p>
        <p>Semaglutide is also considered a "long-acting" GLP-1 receptor agonist, alongside extended-release exenatide and dulaglutide.<xref ref-type="bibr" rid="article-162828.r27">[27]</xref> The extended half-life of semaglutide&#x000a0;may be attributed to&#x000a0;2 structural modifications&#x02014;one modification promotes albumin binding, leading to prolonged renal clearance, whereas the other shields it from metabolic degradation by the dipeptidyl peptidase-4 (DPP-4) enzyme.<xref ref-type="bibr" rid="article-162828.r27">[27]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Subcutaneous semaglutide has high bioavailability (89%), with peak concentration achieved within 1 to 3 days of initiation.<xref ref-type="bibr" rid="article-162828.r28">[28]</xref> Achieving steady-state exposure typically occurs after 4 to 5 weeks of weekly administration, demonstrating a proportional increase with escalating doses up to 2.4 mg.</p>
        <p>Due to the high homology to human GLP-1 peptide, oral semaglutide possesses properties inherent to peptide-like compounds. These include high molecular weight, susceptibility to enzymatic degradation, hydrophilicity, and low permeability, resulting in minimal bioavailability of approximately 0.01%.<xref ref-type="bibr" rid="article-162828.r29">[29]</xref><xref ref-type="bibr" rid="article-162828.r30">[30]</xref><xref ref-type="bibr" rid="article-162828.r31">[31]</xref><xref ref-type="bibr" rid="article-162828.r32">[32]</xref><xref ref-type="bibr" rid="article-162828.r31">[31]</xref>&#x000a0;To&#x000a0;address this limitation, an absorption enhancer called sodium <italic toggle="yes">N</italic>-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC) is incorporated, enhancing the transcellular absorption of oral semaglutide across the gastric mucosa.<xref ref-type="bibr" rid="article-162828.r29">[29]</xref> The commercially available oral semaglutide exhibits an improved, although still minimal, bioavailability range of 0.4% to 1%.<xref ref-type="bibr" rid="article-162828.r33">[33]</xref> Gastric fluid composition, influenced by food and increased water volumes, significantly affects oral semaglutide absorption.<xref ref-type="bibr" rid="article-162828.r29">[29]</xref><xref ref-type="bibr" rid="article-162828.r34">[34]</xref></p>
        <p>After oral administration, the maximum concentration of semaglutide is typically reached within 1 hour post-dose. Steady-state exposure is typically achieved after 4 to 5 weeks of daily administration.<xref ref-type="bibr" rid="article-162828.r35">[35]</xref>&#x000a0;</p>
        <p><bold>Distribution:</bold> Following subcutaneous administration, the mean apparent volume of distribution for semaglutide is approximately 12.5 L.<xref ref-type="bibr" rid="article-162828.r36">[36]</xref>&#x000a0;In healthy subjects, the volume of distribution is approximately 8 L following oral administration.<xref ref-type="bibr" rid="article-162828.r35">[35]</xref>&#x000a0;</p>
        <p><bold>Metabolism:</bold> Semaglutide undergoes metabolism through the proteolytic cleavage of the peptide backbone, followed by sequential &#x003b2;-oxidation of the fatty acid sidechain.<xref ref-type="bibr" rid="article-162828.r37">[37]</xref></p>
        <p><bold>Elimination:</bold> Both oral and subcutaneous semaglutide have an elimination half-life of approximately 1 week, remaining in circulation for about 5 weeks after the last dose. The clearance of subcutaneous semaglutide in individuals with T2DM or obesity or those who are overweight is approximately 0.05 L/h.&#x000a0;In comparison, the clearance of oral semaglutide in healthy subjects is approximately 0.04 L/h.<xref ref-type="bibr" rid="article-162828.r35">[35]</xref><xref ref-type="bibr" rid="article-162828.r36">[36]</xref>&#x000a0;Semaglutide is primarily eliminated in the urine (3% as an unchanged drug) and feces.<xref ref-type="bibr" rid="article-162828.r35">[35]</xref><xref ref-type="bibr" rid="article-162828.r38">[38]</xref></p>
      </sec>
      <sec id="article-162828.s3" sec-type="Administration">
        <title>Administration</title>
        <p>The injection formulations should be administered subcutaneously into the abdomen, thigh, or upper arm. Patients should be advised to rotate injection sites within the same body region (eg, upper arm) to avoid injecting in the same spot each week. Although insulin and semaglutide injections may be administered in the same body region, patients should be cautioned against using the same injection site. Mixing semaglutide injection and insulin directly is not recommended, and it is essential to follow dose escalation instructions diligently to reduce the risk of gastrointestinal adverse events.</p>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>The available&#x000a0;dosage forms for&#x000a0;semaglutide include&#x000a0;subcutaneous injections, such as&#x000a0;Ozempic<sup>&#x000ae;&#x000a0;</sup>and&#x000a0;Wegovy<sup>&#x000ae;</sup>, and oral tablets, such as Rybelsus<sup>&#x000ae;</sup>.</p>
        <p>
<bold>Available Strengths</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Available strengths of Ozempic<sup>&#x000ae;</sup>&#x000a0;as prefilled multidose injection pens include &#x000a0;2 mg/3 mL (3 mL), 4 mg/3 mL (3 mL), and 8 mg/3 mL (3 mL).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Available strengths for Wegovy<sup>&#x000ae;</sup>&#x000a0;as prefilled single-dose injection pens include 0.25 mg/0.5 mL (0.5 mL), &#x000a0;0.5 mg/0.5 mL (0.5 mL), 1 mg/0.5 mL (0.5 mL), 1.7 mg/0.75 mL (0.75 mL) and 2.4 mg/0.75 mL (0.75 mL).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Available strengths for Rybelsus<sup>&#x000ae;</sup>&#x000a0;as oral tablets include 3 mg, 7 mg, and 14 mg.</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>
<bold>Subcutaneous semaglutide for T2DM or reduction of cardiovascular mortality Ozempic<sup>&#x000ae;</sup></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Semaglutide naive:&#x000a0;For semaglutide-naive patients, the recommended dosing regimen starts with 0.25 mg weekly for 4 weeks, followed by a dose escalation to 0.5 mg weekly.
<list list-type="bullet"><list-item><p>The 0.5-mg weekly dosage&#x000a0;can be escalated to 1 mg weekly if glycemic control is inadequate after 4 weeks on the 0.5 mg/week dosage. Furthermore, the 1-mg weekly dosage can be further escalated to 2 mg weekly, which may occur after 4 weeks to achieve glycemic goals.&#x000a0;The maximum recommended dosage is 2 mg weekly.&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Converting from oral semaglutide Rybelsus<italic toggle="yes"><sup>&#x000ae;</sup></italic>&#x000a0;14 mg PO daily: When converting from oral semaglutide Rybelsus<sup>&#x000ae;</sup> 14 mg taken PO daily, the recommended approach is to initiate a dosage of 0.5 mg subcutaneously once weekly starting the day after the final oral dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Converting from oral semaglutide&#x000a0;Rybelsus<italic toggle="yes"><sup>&#x000ae;</sup></italic>&#x000a0;7 mg PO daily:&#x000a0;When transitioning from oral semaglutide Rybelsus&#x000ae; 7 mg taken PO daily, as there is no equivalent oral dose provided in the FDA package insert, one may consider initiating a weekly subcutaneous dose of 0.5 mg beginning the day following the final oral administration.</p>
          </list-item>
        </list>
        <p>
<bold>Special considerations for subcutaneous semaglutide Ozempic<sup>&#x000ae;</sup></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>If a dose of weekly subcutaneous semaglutide is missed, it should be administered promptly within 5 days, and then the regular schedule should be resumed. If more than 5 days have passed, the missed dose can be skipped, and administration can be resumed at the next scheduled weekly dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>When changing the weekly subcutaneous semaglutide administration day, ensuring a minimum of 48 hours between&#x000a0;2 consecutive doses is essential.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Blood glucose should be closely monitored when converting to or from oral semaglutide.</p>
          </list-item>
        </list>
        <p>
<bold>Oral semaglutide for&#x000a0;T2DM Rybelsus<italic toggle="yes"><sup>&#x000ae;</sup></italic></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Semaglutide-naive: For individuals who are semaglutide-naive, the recommended starting dose is 3 mg daily for 30 days, followed by an increase to 7 mg daily. After 30 days on the 7 mg dose, patients may consider escalating to 14 mg daily to achieve their glycemic goals.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Converting from semaglutide injection Ozempic<sup>&#x000ae;&#x000a0;</sup>0.5 mg weekly: When transitioning from semaglutide injection Ozempic<sup>&#x000ae;</sup> 0.5 mg weekly, one may consider switching to either 7 mg or 14 mg taken PO daily for up to 7 days after the last injection. No equivalent dose exists for the 1 mg subcutaneous weekly dosing of Ozempic<sup>&#x000ae;</sup>.</p>
          </list-item>
        </list>
        <p>
<bold>Special considerations for oral semaglutide Rybelsus<sup>&#x000ae;</sup></bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>If a dose of oral semaglutide is missed, the individual should skip the missed dose and resume with the next scheduled dose.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>To ensure optimal absorption of oral semaglutide, it should be administered at least 30 minutes before the first consumption of food, beverages, or other medications of the day. The medication should be ingested with no more than 4 ounces (120 mL) of water. The lower initial dose for both weekly subcutaneous semaglutide and daily oral semaglutide aims to mitigate gastrointestinal symptoms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>When individuals convert to or from oral semaglutide, monitoring their blood glucose levels closely is crucial.</p>
          </list-item>
        </list>
        <p>
<bold>Subcutaneous semaglutide for chronic weight management Wegovy<sup>&#x000ae;</sup></bold>
</p>
        <p>For chronic weight management with subcutaneous semaglutide (Wegovy<sup>&#x000ae;</sup>), it is necessary to follow the following steps:</p>
        <list list-type="bullet">
          <list-item>
            <p>Wegovy<sup>&#x000ae;</sup>&#x000a0;dosage should be administered 0.25 mg weekly for the first 4 weeks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wegovy<sup>&#x000ae;</sup> dosage should be increased to 0.5 mg weekly for weeks 5 through 8.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wegovy<sup>&#x000ae;</sup>&#x000a0;dosage should be further increased to 1 mg weekly for weeks 9 through 12.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wegovy<sup>&#x000ae;</sup>&#x000a0;dosage should be&#x000a0;further progressed to 1.7 mg weekly for weeks 13 through 16.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Finally, Wegovy<sup>&#x000ae;</sup>&#x000a0;should be maintained at a dosage of 2.4 mg weekly thereafter.</p>
          </list-item>
        </list>
        <p>
<bold>Special considerations for subcutaneous semaglutide (Wegovy<sup>&#x000ae;</sup>)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>If patients experience difficulty with a dosage increase, healthcare providers should consider postponing the increase for an additional 4 weeks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If the 2.4 mg weekly dosage is not well tolerated, healthcare providers may consider reducing the dose to 1.7 mg weekly for a maximum of 4 weeks. After this period, the dosage should be increased to 2.4 mg weekly. If the patient continues to experience intolerance, discontinuing semaglutide (Wegovy<sup>&#x000ae;</sup>) should be considered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If a dose is missed and the next scheduled dose is more than 2 days away (48 hours), it should be administered as soon as possible. However, if a dose is missed and the next scheduled dose is less than 2 days away (48 hours), it should not be administered. In such cases, the patient should resume dosing on the regularly scheduled day of the week.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If 2 or more consecutive doses are missed, the patient should resume dosing as scheduled. If necessary, they may reinitiate and follow the dose escalation schedule, which may help reduce the occurrence of gastrointestinal symptoms associated with restarting treatment.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>No dosage adjustment is needed for subcutaneous or oral semaglutide in patients with hepatic impairment.<xref ref-type="bibr" rid="article-162828.r39">[39]</xref><xref ref-type="bibr" rid="article-162828.r40">[40]</xref></p>
        <p><bold>Renal impairment:&#x000a0;</bold>No dosage adjustment is necessary for subcutaneous or oral semaglutide in mild-to-severe impairment.<xref ref-type="bibr" rid="article-162828.r37">[37]</xref><xref ref-type="bibr" rid="article-162828.r41">[41]</xref>&#x000a0;Caution should be exercised when initiating or escalating doses.</p>
        <p>The manufacturer advises against adjusting the dosage of subcutaneous and oral Semaglutide for patients undergoing three or more weekly hemodialysis sessions. However, due to limited clinical evidence, caution is advised. Furthermore, the manufacturer recommends against adjusting the subcutaneous and oral semaglutide dosage for patients undergoing peritoneal dialysis. Again, caution is advised due to limited clinical evidence.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>Current clinical trial data and pharmacovigilance reports on semaglutide use in pregnant women are insufficient to ascertain its association with significant congenital defects, miscarriage, or adverse outcomes for both the mother and the fetus. However, findings from animal reproduction studies indicate potential risks to the fetus with semaglutide exposure during pregnancy. In addition, the weight loss effects of semaglutide are not deemed beneficial for pregnant individuals and may pose a risk of harm to the fetus. As a result, the manufacturer recommends against the use of semaglutide during pregnancy due to the potential fetal risks.</p>
        <p>For the management of diabetes mellitus or weight loss, discontinuation of semaglutide is advised for a minimum of 2 months before attempting to conceive. According to the 2021 guidelines from the American College of Obstetricians and Gynecologists (ACOG), weight loss medications are not recommended at conception.<xref ref-type="bibr" rid="article-162828.r42">[42]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Insufficient data exist regarding semaglutide or its metabolites in human milk and the potential effects on breastfed infants and milk production. Semaglutide was identified in milk at levels 3 to 12 times lower than in maternal plasma in lactating rats. Although information on the impact of semaglutide in human milk is unavailable, it may be present in human milk if present in animal milk. The decision to use injectable semaglutide while breastfeeding should carefully consider the potential risk of infant exposure versus the benefits of breastfeeding.</p>
        <p>Regarding the oral formulation containing SNAC, it is unclear whether SNAC is excreted in breast milk. Due to this uncertainty, oral semaglutide is not recommended during breastfeeding, as the unknown risk of SNAC accumulation in infants is a concern.</p>
        <p><bold>Pediatric patients:</bold> The&#x000a0;safety and efficacy of subcutaneous semaglutide (Ozempic<sup>&#x000ae;</sup>) and oral semaglutide (Rybelsus<sup>&#x000ae;</sup>) have not been established in individuals aged 18 or younger. However, Wegovy<sup>&#x000ae;</sup>, specifically indicated for weight loss, is approved for use in pediatric patients aged 12 and older with a BMI corresponding to &#x02265;95th percentile standardized for age and sex. This approval is based on a 68-week, double-blind, placebo-controlled clinical trial (STEP TEENS) involving 201 pediatric patients aged 12 and older with a BMI corresponding to &#x02265;95th percentile for age and sex.<xref ref-type="bibr" rid="article-162828.r21">[21]</xref></p>
        <p>The approved dosage for chronic weight management in the pediatric and adolescent age groups of &#x02265;12 and &#x02264;18 is similar to the adult dosing outlined earlier, with the following exceptions:</p>
        <list list-type="bullet">
          <list-item>
            <p>If patients do not tolerate the 2.4 mg weekly, the maintenance dosage may be reduced to 1.7 mg indefinitely.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If the 1.7 mg weekly dose is not tolerated, semaglutide should be discontinued.</p>
          </list-item>
        </list>
        <p>Notably,&#x000a0;cholelithiasis, cholecystitis, hypotension, rash, and urticaria were more prevalent in this younger age group than in adults treated with Wegovy<sup>&#x000ae;</sup>. Meticulous attention to the dose escalation strategy may help mitigate the incidence of adverse events.<bold>&#x000a0;</bold></p>
        <p><bold>Older patients:&#x000a0;</bold>No overall differences in safety and efficacy have been observed in patients aged 65 and older.</p>
      </sec>
      <sec id="article-162828.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Adverse Drug Reactions</bold>
</p>
        <p>Adverse drug reactions caused by semaglutide&#x000a0;are listed below.</p>
        <p><bold>Hypoglycemia:&#x000a0;</bold>GLP-1 agonists lower blood glucose and may cause hypoglycemia. The risk of hypoglycemia significantly increases with escalating doses and when semaglutide is administered with other anti-hyperglycemic medications such as sulfonylureas, metformin, or insulin.&#x000a0;</p>
        <p><bold>Gastrointestinal:</bold> The adverse effects most frequently reported and most associated with discontinuation of semaglutide include nausea, vomiting, abdominal pain, constipation, and diarrhea.<xref ref-type="bibr" rid="article-162828.r43">[43]</xref>&#x000a0;Nearly one-fifth of all patients in clinical trials with Ozempic<sup>&#x000ae;</sup> and Rybelsus<sup>&#x000ae;</sup>&#x000a0;experienced nausea, which is the most prevalent adverse effect,&#x000a0;whereas&#x000a0;44% of patients treated with Wegovy<sup>&#x000ae;</sup>&#x000a0;reported the same adverse effects. In addition, decreased appetite, dysgeusia, and dyspepsia have been documented. Although the precise mechanism behind these effects is not entirely elucidated, it may stem from delayed gastric emptying or the activation of brain centers implicated in appetite regulation, satiety, and nausea.<xref ref-type="bibr" rid="article-162828.r44">[44]</xref>&#x000a0;Higher doses and dose escalations are&#x000a0;associated with the risk of these adverse effects.</p>
        <p><bold>Renal:</bold> Semaglutide can result in acute kidney injury. Patients who experienced nausea, vomiting, diarrhea, or dehydration during the treatment were at the highest risk of acute kidney injury, with volume depletion being the suspected link. Discontinuation or dose reduction of semaglutide is recommended rather than relying solely on symptomatic treatment of volume depletion.</p>
        <p><bold>Gallbladder disorders:</bold> Semaglutide has been associated with gallbladder and biliary tract issues, including cholelithiasis and cholecystitis.<xref ref-type="bibr" rid="article-162828.r45">[45]</xref> The exact mechanism behind this adverse effect is not entirely understood. Animal studies and in vitro data&#x000a0;suggest that GLP-1 enhances cholangiocyte proliferation and functional activity, which could contribute to gallbladder diseases.<xref ref-type="bibr" rid="article-162828.r46">[46]</xref>&#x000a0;Some authors have proposed that semaglutide can potentially suppress cholecystokinin secretion, reduce gallbladder emptying, and prolong gallbladder refilling, or a combination of these factors contributing to gallbladder disease.<xref ref-type="bibr" rid="article-162828.r47">[47]</xref></p>
        <p><bold>Anaphylaxis and angioedema:</bold> GLP-1 receptor agonists (GLP-1 RAs) can induce severe type 1 hypersensitivity reactions, such as anaphylaxis and angioedema.<xref ref-type="bibr" rid="article-162828.r48">[48]</xref><xref ref-type="bibr" rid="article-162828.r49">[49]</xref>&#x000a0;A possibility of cross-reactivity among different GLP-1 receptor agonists exists. Therefore, caution is advised when prescribing&#x000a0;semaglutide to patients with a history of anaphylaxis or angioedema in response to other&#x000a0;GLP-1 receptor agonists, pending further studies.</p>
        <p><bold>Pancreatitis:</bold> Although cases of acute pancreatitis have been associated with semaglutide use, findings from the SUSTAIN 6 trial indicate a similar incidence rate of pancreatitis with semaglutide compared to the placebo group.<xref ref-type="bibr" rid="article-162828.r6">[6]</xref> The causal relationship between semaglutide and acute pancreatitis has not been definitively established. GLP-1 receptor agonists directly stimulate GLP-1 receptors in pancreatic islet beta cells and exocrine duct cells. Researchers suggest that this stimulation may lead to the overgrowth of cells covering smaller ducts, causing hyperplasia, increased pancreatic weight, duct occlusion, back pressure, and subsequent acute or chronic inflammation.<xref ref-type="bibr" rid="article-162828.r50">[50]</xref></p>
        <p><bold>Diabetic retinopathy:&#x000a0;</bold>Semaglutide use may potentially elevate the risk of diabetic retinopathy, particularly in patients with retinopathy at baseline. The exact relationship between semaglutide and the development or exacerbation of diabetic retinopathy remains incompletely understood. However, it may be associated with rapid improvements in glucose control, as identified in other studies.<xref ref-type="bibr" rid="article-162828.r51">[51]</xref></p>
        <p><bold>Risk of thyroid C-cell tumors:</bold> During the initial phases of drug development, animal studies involving semaglutide revealed the development of thyroid C-cell tumors. However, the potential association between semaglutide and thyroid cancers in humans remains unclear. Individuals with a personal or family history of medullary thyroid carcinoma (MTC) or those diagnosed with multiple endocrine neoplasia type 2 (MEN 2) syndrome may face an elevated risk. The manufacturer acknowledges reported cases of MTC associated with liraglutide, which is another GLP-1 receptor agonist.</p>
        <p><bold>Additional adverse reactions:</bold>&#x000a0;Other reported adverse reactions associated with semaglutide include fatigue, headache, rash, alopecia, vitreous hemorrhage in patients with diabetic retinopathy, anxiety, dizziness, discomfort at the injection site, and erythema at the injection site.</p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Semaglutide causes a delay in gastric emptying,&#x000a0;which may lead to delayed absorption of concurrently administered oral medications. However, clinical pharmacology trials with subcutaneously administered semaglutide have demonstrated no significant impact on the absorption of orally administered medications. Nonetheless, cautious monitoring of the effects of oral medications is recommended when used concurrently with semaglutide, especially those with a narrow therapeutic window.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>When semaglutide is used alongside other blood-glucose-lowering agents, there is a notable risk of hypoglycemia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Semaglutide should not be used with other GLP-1 receptor agonists or tirzepatide, as they are contraindicated.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>When semaglutide is administered alongside insulins or insulin secretagogues, such as sulfonylureas, it is recommended to consider reducing the dosage of these medications to mitigate the risk of hypoglycemia.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Medications that have the potential to augment the hypoglycemic effects of semaglutide include beta-blockers, monoamine oxidase inhibitors, androgens, quinolones, salicylates, selective serotonin reuptake inhibitors, and other antidiabetic medications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Medications that may diminish the therapeutic effects of semaglutide include furosemide, thiazide diuretics, and ritodrine.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Semaglutide may increase the serum concentrations of levothyroxine.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-162828.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Semaglutide has been shown to induce dose-dependent and treatment-duration&#x02013;dependent thyroid C-cell tumors in rodents. However, it remains uncertain whether semaglutide poses a similar risk of cancer in humans. This aspect may become more apparent as more data on this medication become available over the next few years. Given this potential risk, semaglutide is contraindicated in patients with a personal or family history of MTC or MEN 2 syndrome. Patients prescribed semaglutide should receive counseling regarding the potential risk of thyroid cancers.&#x000a0;</p>
        <p>
<bold>Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Suicidal behavior has been reported with other medications prescribed for weight management. Therefore, it is advisable to avoid the use of Semaglutide in individuals with a history of suicidal attempts or current suicidal ideation. Patients with suicidal ideations should seek immediate assistance.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Semaglutide can potentially slow gastric emptying and impede the absorption of other medications.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The multiple-dose injection pen (Ozempic<sup>&#x000ae;</sup>) should not be shared among individuals to mitigate the risk of infection transmitting infections.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Semaglutide is contraindicated in patients with type 1 diabetes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As the effectiveness of semaglutide in combination with other weight loss medications is not established, concurrent use of this drug with other weight loss medications should be avoided.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with a history of bariatric surgery face an increased risk of gastrointestinal complications when using semaglutide. Therefore, regular monitoring for such complications is recommended.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If the medication is discontinued after attaining weight loss, a risk of rebound weight gain exists. This was demonstrated in an extension of the STEP 1 trial, where participants, after discontinuing weekly subcutaneous semaglutide 2.4 mg and lifestyle interventions for 1 year, experienced a regain of approximately two-thirds of their initial weight loss.<xref ref-type="bibr" rid="article-162828.r52">[52]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-162828.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Before initiating and periodically during treatment with either oral or subcutaneously administered semaglutide, patients should receive counseling regarding potential adverse effects or complications. They should also be instructed to report any concerns to their healthcare providers promptly.</p>
        <p>Monitoring for complications should be conducted collaboratively by the patient and their clinician, focusing on the following aspects:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vigilance for hypoglycemia is essential, especially when semaglutide is used with other glucose-lowering agents.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Due to a heightened risk of gastrointestinal adverse effects such as nausea, vomiting, diarrhea, and constipation, close&#x000a0;monitoring of patients for these adverse reactions is essential, with meticulous adherence to dose escalation.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Dehydration resulting from gastrointestinal adverse effects poses a potential risk of renal failure. Therefore, monitoring renal function is paramount, especially in individuals experiencing gastrointestinal adverse effects.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Healthcare providers should assess the risk of gallbladder or ductal disease and pancreatitis in patients using semaglutide who exhibit characteristic signs or symptoms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>A potential risk of diabetic retinopathy complications underscores the importance of monitoring for any changes in vision and providing exceptional care to patients with baseline retinopathy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Although the risk of thyroid tumors in humans remains unclear, patients and healthcare providers should&#x000a0;remain vigilant for the development of any signs, such as a neck lump, hoarseness, dyspnea, or dysphagia while on semaglutide.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-162828.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Overdose with oral or subcutaneous semaglutide can cause severe nausea, vomiting, and hypoglycemia.</p>
        <p>Oral semaglutide&#x000a0;is often co-administered with&#x000a0;SNAC to increase gastric absorbability. Animal studies have indicated that higher SNAC exposure can result in lethargy, abnormal respiration, ataxia, and reduced activity.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>In case of an overdose with oral or subcutaneous semaglutide, management involves implementing suitable supportive measures according to observed signs and symptoms. Consultation with poison control or a toxicologist is recommended. Due to the long half-life of semaglutide, an extended period of observation and treatment may be necessary.</p>
      </sec>
      <sec id="article-162828.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The collaborative efforts of the healthcare team, including the physician or advanced practice clinician, pharmacist, dietitian, and nurse, are essential for achieving optimal outcomes in managing T2DM, reducing cardiovascular death, or facilitating weight loss with semaglutide treatment. Effective communication and collaboration among team members are fundamental for reaching treatment goals. As the comprehensive benefits of semaglutide are intricately linked to lifestyle modifications, dietitians are&#x000a0;crucial in providing tailored recommendations for glucose-lowering, cardiovascular protection, and weight loss.</p>
        <p>The gradual dose escalation of semaglutide and the potential for increased adverse effects at higher doses emphasize the importance of proactive counseling by the healthcare team, including the patient's pharmacist. Close monitoring of the patient ensures adherence to the appropriate dose and facilitates early detection of adverse effects. Pharmacists and nurses, in particular, play crucial roles in promptly reporting any observed adverse effects to the physician, who can then consider necessary interventions such as dosage adjustments or discontinuation of the drug based on the severity of the adverse effects. Pharmacists can also identify potential drug-drug interactions and collaborate with the treating physician. This collective approach, involving each team member's expertise, enhances patient outcomes in semaglutide treatment.</p>
      </sec>
      <sec id="article-162828.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=162828&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=162828">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/162828/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=162828">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-162828.s10">
        <title>References</title>
        <ref id="article-162828.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harashima</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Tsoukas</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Unger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karsb&#x000f8;l</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-260</page-range>
            <pub-id pub-id-type="pmid">28110911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahr&#x000e9;n</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Masmiquel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sargin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Karsb&#x000f8;l</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2017</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>341</fpage>
            <page-range>341-354</page-range>
            <pub-id pub-id-type="pmid">28385659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmann</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Capehorn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Charpentier</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dotta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Henkel</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Annett</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.</article-title>
            <source>Diabetes Care</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>258</fpage>
            <page-range>258-266</page-range>
            <pub-id pub-id-type="pmid">29246950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Cariou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pileti&#x0010d;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Axelsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>DeVries</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2017</year>
            <month>May</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>355</fpage>
            <page-range>355-366</page-range>
            <pub-id pub-id-type="pmid">28344112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodbard</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de la Rosa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Wijayasinghe</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Norwood</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>2291</fpage>
            <page-range>2291-2301</page-range>
            <pub-id pub-id-type="pmid">29688502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marso</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Consoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eliaschewitz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>J&#x000f3;dar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seufert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Holst</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vilsb&#x000f8;ll</surname>
                <given-names>T</given-names>
              </name>
              <collab>SUSTAIN-6 Investigators</collab>
            </person-group>
            <article-title>Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Nov</month>
            <day>10</day>
            <volume>375</volume>
            <issue>19</issue>
            <fpage>1834</fpage>
            <page-range>1834-1844</page-range>
            <pub-id pub-id-type="pmid">27633186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Terauchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Altuntas</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lalic</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Morales Villegas</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Jeppesen</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Haluz&#x000ed;k</surname>
                <given-names>M</given-names>
              </name>
              <collab>PIONEER 1 Investigators</collab>
            </person-group>
            <article-title>PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.</article-title>
            <source>Diabetes Care</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>9</issue>
            <fpage>1724</fpage>
            <page-range>1724-1732</page-range>
            <pub-id pub-id-type="pmid">31186300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodbard</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Canani</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Deerochanawong</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gumprecht</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lindberg</surname>
                <given-names>S&#x000d8;</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>S&#x000f8;ndergaard</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Treppendahl</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Montanya</surname>
                <given-names>E</given-names>
              </name>
              <collab>PIONEER 2 Investigators</collab>
            </person-group>
            <article-title>Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.</article-title>
            <source>Diabetes Care</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>12</issue>
            <fpage>2272</fpage>
            <page-range>2272-2281</page-range>
            <pub-id pub-id-type="pmid">31530666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Birkenfeld</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Blicher</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Deenadayalan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Serusclat</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Violante</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Watada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <collab>PIONEER 3 Investigators</collab>
            </person-group>
            <article-title>Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2019</year>
            <month>Apr</month>
            <day>16</day>
            <volume>321</volume>
            <issue>15</issue>
            <fpage>1466</fpage>
            <page-range>1466-1480</page-range>
            <pub-id pub-id-type="pmid">30903796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pratley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amod</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Kadowaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nauck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Saugstrup</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>JJ</given-names>
              </name>
              <collab>PIONEER 4 investigators</collab>
            </person-group>
            <article-title>Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.</article-title>
            <source>Lancet</source>
            <year>2019</year>
            <month>Jul</month>
            <day>06</day>
            <volume>394</volume>
            <issue>10192</issue>
            <fpage>39</fpage>
            <page-range>39-50</page-range>
            <pub-id pub-id-type="pmid">31186120</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mosenzon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Blicher</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Rosenlund</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hels</surname>
                <given-names>OH</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sathyapalan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Desouza</surname>
                <given-names>C</given-names>
              </name>
              <collab>PIONEER 5 Investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>515</fpage>
            <page-range>515-527</page-range>
            <pub-id pub-id-type="pmid">31189517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pieber</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Bode</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Wallenstein</surname>
                <given-names>SOR</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <collab>PIONEER 7 investigators</collab>
            </person-group>
            <article-title>Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>528</fpage>
            <page-range>528-539</page-range>
            <pub-id pub-id-type="pmid">31189520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zinman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Buse</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cariou</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hoff</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Tarp-Johansen</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>E</given-names>
              </name>
              <collab>PIONEER 8 Investigators</collab>
            </person-group>
            <article-title>Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.</article-title>
            <source>Diabetes Care</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>42</volume>
            <issue>12</issue>
            <fpage>2262</fpage>
            <page-range>2262-2271</page-range>
            <pub-id pub-id-type="pmid">31530667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Husain</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Birkenfeld</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Donsmark</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eliaschewitz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Jeppesen</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mosenzon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Tack</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vilsb&#x000f8;ll</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>SC</given-names>
              </name>
              <collab>PIONEER 6 Investigators</collab>
            </person-group>
            <article-title>Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.</article-title>
            <source>N Engl J Med</source>
            <year>2019</year>
            <month>Aug</month>
            <day>29</day>
            <volume>381</volume>
            <issue>9</issue>
            <fpage>841</fpage>
            <page-range>841-851</page-range>
            <pub-id pub-id-type="pmid">31185157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilding</surname>
                <given-names>JPH</given-names>
              </name>
              <name>
                <surname>Batterham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Calanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Gaal</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>MTD</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokote</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zeuthen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>RF</given-names>
              </name>
              <collab>STEP 1 Study Group</collab>
            </person-group>
            <article-title>Once-Weekly Semaglutide in Adults with Overweight or Obesity.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Mar</month>
            <day>18</day>
            <volume>384</volume>
            <issue>11</issue>
            <fpage>989</fpage>
            <page-range>989-1002</page-range>
            <pub-id pub-id-type="pmid">33567185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Billings</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frias</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Koroleva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rubino</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Skovgaard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wallenstein</surname>
                <given-names>SOR</given-names>
              </name>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <collab>STEP 3 Investigators</collab>
            </person-group>
            <article-title>Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Apr</month>
            <day>13</day>
            <volume>325</volume>
            <issue>14</issue>
            <fpage>1403</fpage>
            <page-range>1403-1413</page-range>
            <pub-id pub-id-type="pmid">33625476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Abrahamsson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hesse</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Greenway</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mosenzon</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rudofsky</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tadayon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Dicker</surname>
                <given-names>D</given-names>
              </name>
              <collab>STEP 4 Investigators</collab>
            </person-group>
            <article-title>Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2021</year>
            <month>Apr</month>
            <day>13</day>
            <volume>325</volume>
            <issue>14</issue>
            <fpage>1414</fpage>
            <page-range>1414-1425</page-range>
            <pub-id pub-id-type="pmid">33755728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Batterham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Bhatta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Buscemi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Frias</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>J&#x000f3;dar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kandler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rigas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>S</given-names>
              </name>
              <collab>STEP 5 Study Group</collab>
            </person-group>
            <article-title>Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.</article-title>
            <source>Nat Med</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>10</issue>
            <fpage>2083</fpage>
            <page-range>2083-2091</page-range>
            <pub-id pub-id-type="pmid">36216945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>F&#x000e6;rch</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jeppesen</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Pakseresht</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Perreault</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shimomura</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Viljoen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <collab>STEP 2 Study Group</collab>
            </person-group>
            <article-title>Semaglutide 2&#x000b7;4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.</article-title>
            <source>Lancet</source>
            <year>2021</year>
            <month>Mar</month>
            <day>13</day>
            <volume>397</volume>
            <issue>10278</issue>
            <fpage>971</fpage>
            <page-range>971-984</page-range>
            <pub-id pub-id-type="pmid">33667417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubino</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Greenway</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Khalid</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>O'Neil</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rrig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wizert</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garvey</surname>
                <given-names>WT</given-names>
              </name>
              <collab>STEP 8 Investigators</collab>
            </person-group>
            <article-title>Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2022</year>
            <month>Jan</month>
            <day>11</day>
            <volume>327</volume>
            <issue>2</issue>
            <fpage>138</fpage>
            <page-range>138-150</page-range>
            <pub-id pub-id-type="pmid">35015037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weghuber</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barrientos-P&#x000e9;rez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gies</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hesse</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jeppesen</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mastrandrea</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rrig</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arslanian</surname>
                <given-names>S</given-names>
              </name>
              <collab>STEP TEENS Investigators</collab>
            </person-group>
            <article-title>Once-Weekly Semaglutide in Adolescents with Obesity.</article-title>
            <source>N Engl J Med</source>
            <year>2022</year>
            <month>Dec</month>
            <day>15</day>
            <volume>387</volume>
            <issue>24</issue>
            <fpage>2245</fpage>
            <page-range>2245-2257</page-range>
            <pub-id pub-id-type="pmid">36322838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>R&#x000f8;der</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Clinical potential of treatment with semaglutide in type 2 diabetes patients.</article-title>
            <source>Drugs Context</source>
            <year>2019</year>
            <volume>8</volume>
            <fpage>212585</fpage>
            <pub-id pub-id-type="pmid">31844422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meier</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>728</fpage>
            <page-range>728-42</page-range>
            <pub-id pub-id-type="pmid">22945360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Massadi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fern&#x000f8;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Di&#x000e9;guez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nogueiras</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Qui&#x000f1;ones</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Glucagon Control on Food Intake and Energy Balance.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Aug</month>
            <day>11</day>
            <volume>20</volume>
            <issue>16</issue>
            <pub-id pub-id-type="pmid">31405212</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Drucker</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.</article-title>
            <source>Cell Metab</source>
            <year>2018</year>
            <month>Apr</month>
            <day>03</day>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>740</fpage>
            <page-range>740-756</page-range>
            <pub-id pub-id-type="pmid">29617641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knudsen</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Discovery and Development of Liraglutide and Semaglutide.</article-title>
            <source>Front Endocrinol (Lausanne)</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>155</fpage>
            <pub-id pub-id-type="pmid">31031702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guja</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>D&#x00103;nciulescu Miulescu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Semaglutide-the "<italic>new kid on the block</italic>" in the field of glucagon-like peptide-1 receptor agonists?</article-title>
            <source>Ann Transl Med</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>5</volume>
            <issue>23</issue>
            <fpage>475</fpage>
            <pub-id pub-id-type="pmid">29285508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Overgaard</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Delff</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Petri</surname>
                <given-names>KCC</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ingwersen</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Population Pharmacokinetics of Semaglutide for Type 2 Diabetes.</article-title>
            <source>Diabetes Ther</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>649</fpage>
            <page-range>649-662</page-range>
            <pub-id pub-id-type="pmid">30788808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buckley</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>B&#x000e6;kdal</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Vegge</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maarbjerg</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Pyke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ahnfelt-R&#x000f8;nne</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Madsen</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Sch&#x000e9;ele</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Alanentalo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Skyggebjerg</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Benie</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Wahlund</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Bjerregaard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Farkas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fekete</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>S&#x000f8;ndergaard</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Borregaard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hartoft-Nielsen</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.</article-title>
            <source>Sci Transl Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>14</day>
            <volume>10</volume>
            <issue>467</issue>
            <pub-id pub-id-type="pmid">30429357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aroda</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Blonde</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pratley</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.</article-title>
            <source>Rev Endocr Metab Disord</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>979</fpage>
            <page-range>979-994</page-range>
            <pub-id pub-id-type="pmid">35838946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zargar</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2022</year>
            <season>Mar-Apr</season>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>98</fpage>
            <page-range>98-105</page-range>
            <pub-id pub-id-type="pmid">35873937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aguirre</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Teijeiro-Osorio</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coulter</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Brayden</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials.</article-title>
            <source>Adv Drug Deliv Rev</source>
            <year>2016</year>
            <month>Nov</month>
            <day>15</day>
            <volume>106</volume>
            <issue>Pt B</issue>
            <fpage>223</fpage>
            <page-range>223-241</page-range>
            <pub-id pub-id-type="pmid">26921819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>McEntee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery.</article-title>
            <source>Drug Deliv Transl Res</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">34024013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Overgaard</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Navarria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ingwersen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>B&#x000e6;kdal</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Kildemoes</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>60</volume>
            <issue>10</issue>
            <fpage>1335</fpage>
            <page-range>1335-1348</page-range>
            <pub-id pub-id-type="pmid">33969456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dimitriou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Semaglutide: A Novel Oral Glucagon-Like Peptide Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.</article-title>
            <source>Cardiol Rev</source>
            <string-date>2021 Mar-Apr 01</string-date>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>100</fpage>
            <page-range>100-108</page-range>
            <pub-id pub-id-type="pmid">32897887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlsson Petri</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Ingwersen</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zacho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Overgaard</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis.</article-title>
            <source>Diabetes Ther</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>1533</fpage>
            <page-range>1533-1547</page-range>
            <pub-id pub-id-type="pmid">29907893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Granhall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>S&#x000f8;ndergaard</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>57</volume>
            <issue>12</issue>
            <fpage>1571</fpage>
            <page-range>1571-1580</page-range>
            <pub-id pub-id-type="pmid">29623579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Helleberg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Roffel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van Lier</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Bj&#x000f8;rnsdottir</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rowe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Derving Karsb&#x000f8;l</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species.</article-title>
            <source>Eur J Pharm Sci</source>
            <year>2017</year>
            <month>Jun</month>
            <day>15</day>
            <volume>104</volume>
            <fpage>31</fpage>
            <page-range>31-41</page-range>
            <pub-id pub-id-type="pmid">28323117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kupcova</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arold</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hjerpsted</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>998</fpage>
            <page-range>998-1005</page-range>
            <pub-id pub-id-type="pmid">29205786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baekdal</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Thomsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kup&#x0010d;ov&#x000e1;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>58</volume>
            <issue>10</issue>
            <fpage>1314</fpage>
            <page-range>1314-1323</page-range>
            <pub-id pub-id-type="pmid">29693715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marbury</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Flint</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Derving Karsb&#x000f8;l</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lasseter</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>56</volume>
            <issue>11</issue>
            <fpage>1381</fpage>
            <page-range>1381-1390</page-range>
            <pub-id pub-id-type="pmid">28349386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <article-title>Obesity in Pregnancy: ACOG Practice Bulletin, Number 230.</article-title>
            <source>Obstet Gynecol</source>
            <year>2021</year>
            <month>Jun</month>
            <day>01</day>
            <volume>137</volume>
            <issue>6</issue>
            <fpage>e128</fpage>
            <page-range>e128-e144</page-range>
            <pub-id pub-id-type="pmid">34011890</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Htike</surname>
                <given-names>ZZ</given-names>
              </name>
              <name>
                <surname>Zaccardi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Papamargaritis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Khunti</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>524</fpage>
            <page-range>524-536</page-range>
            <pub-id pub-id-type="pmid">27981757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Filippatos</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Panagiotopoulou</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Elisaf</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Adverse Effects of GLP-1 Receptor Agonists.</article-title>
            <source>Rev Diabet Stud</source>
            <year>2014</year>
            <season>Fall-Winter</season>
            <volume>11</volume>
            <issue>3-4</issue>
            <fpage>202</fpage>
            <page-range>202-30</page-range>
            <pub-id pub-id-type="pmid">26177483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>He</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ping</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.</article-title>
            <source>JAMA Intern Med</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>182</volume>
            <issue>5</issue>
            <fpage>513</fpage>
            <page-range>513-519</page-range>
            <pub-id pub-id-type="pmid">35344001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marzioni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alpini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Saccomanno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Candelaresi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Venter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rychlicki</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Trozzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis.</article-title>
            <source>Gastroenterology</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>133</volume>
            <issue>1</issue>
            <fpage>244</fpage>
            <page-range>244-55</page-range>
            <pub-id pub-id-type="pmid">17631146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gether</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Nex&#x000f8;e-Larsen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Knop</surname>
                <given-names>FK</given-names>
              </name>
            </person-group>
            <article-title>New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2019</year>
            <month>Jul</month>
            <day>01</day>
            <volume>104</volume>
            <issue>7</issue>
            <fpage>2463</fpage>
            <page-range>2463-2472</page-range>
            <pub-id pub-id-type="pmid">30137354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Tadeo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Callero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Plata</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Robaina</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>A case report of allergy to exenatide.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2014</year>
            <season>Nov-Dec</season>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>822</fpage>
            <page-range>822-3</page-range>
            <pub-id pub-id-type="pmid">25439386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pradhan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Montastruc</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rousseau</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patorno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Azoulay</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis.</article-title>
            <source>Lancet Diabetes Endocrinol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-14</page-range>
            <pub-id pub-id-type="pmid">31806579</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Knapen</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>de Jong</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Driessen</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Keulemans</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>van Erp</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>De Bruin</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Leufkens</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Croes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>401</fpage>
            <page-range>401-411</page-range>
            <pub-id pub-id-type="pmid">27883260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ntentakis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Correa</surname>
                <given-names>VSMC</given-names>
              </name>
              <name>
                <surname>Ntentaki</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Delavogia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Narimatsu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Efstathiou</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Vavvas</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>262</volume>
            <issue>3</issue>
            <fpage>717</fpage>
            <page-range>717-752</page-range>
            <pub-id pub-id-type="pmid">37728754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-162828.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilding</surname>
                <given-names>JPH</given-names>
              </name>
              <name>
                <surname>Batterham</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Van Gaal</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Kandler</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Konakli</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lingvay</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>McGowan</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Oral</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Rosenstock</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wadden</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wharton</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yokote</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>RF</given-names>
              </name>
              <collab>STEP 1 Study Group</collab>
            </person-group>
            <article-title>Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>8</issue>
            <fpage>1553</fpage>
            <page-range>1553-1564</page-range>
            <pub-id pub-id-type="pmid">35441470</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
